Accumulation of Alkyl-lysophosphatidylcholines in Niemann-Pick Disease Type C1

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2024 Jul 24

PMID 39048052

Authors

Sonali Mishra

Pamela Kell

David Scherrer

Dennis J Dietzen

Charles H Vite

Elizabeth Berry-Kravis

Cristin Davidson

Stephanie M Cologna

Forbes D Porter

Daniel S Ory

Xuntian Jiang

Affiliations

Soon will be listed here.

Abstract

Lysosomal function is impaired in Niemann-Pick disease type C1 (NPC1), a rare and inherited neurodegenerative disorder, resulting in late endosomal/lysosomal accumulation of unesterified cholesterol. The precise pathogenic mechanism of NPC1 remains incompletely understood. In this study, we employed metabolomics to uncover secondary accumulated substances in NPC1. Our findings unveiled a substantial elevation in the levels of three alkyl-lysophosphatidylcholine [alkyl-LPC, also known as lyso-platelet activating factor (PAF)] species in NPC1 compared to controls across various tissues, including brain tissue from individuals with NPC1, liver, spleen, cerebrum, cerebellum, and brain stem from NPC1 mice, as well as in both brain and liver tissue from NPC1 cats. The three elevated alkyl-LPC species were as follows: LPC O-16:0, LPC O-18:1, and LPC O-18:0. However, the levels of PAF 16:0, PAF 18:1, and PAF 18:0 were not altered in NPC1. In the NPC1 feline model, the brain and liver alkyl-LPC levels were reduced following 2-hydroxypropyl-β-cyclodextrin (HPβCD) treatment, suggesting that alkyl-LPCs are secondary storage metabolites in NPC1 disease. Unexpectedly, cerebrospinal fluid (CSF) levels of LPC O-16:0 and LPC O-18:1 were decreased in individuals with NPC1 compared to age-appropriate comparison samples, and their levels were increased in 80% of participants 2 years after intrathecal HPβCD treatment. The fold increases in CSF LPC O-16:0 and LPC O-18:1 levels were more pronounced in responders compared to nonresponders. This study identified alkyl-LPC species as secondary storage metabolites in NPC1 and indicates that LPC O-16:0 and LPC O-18:1, in particular, could serve as potential biomarkers for tracking treatment response in NPC1 patients.

References

Kirkegaard T, Gray J, Priestman D, Wallom K, Atkins J, Olsen O . Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med. 2016; 8(355):355ra118. PMC: 6821533. DOI: 10.1126/scitranslmed.aad9823. View

Mattsson N, Zetterberg H, Bianconi S, Yanjanin N, Fu R, Mansson J . Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology. 2011; 76(4):366-72. PMC: 3034414. DOI: 10.1212/WNL.0b013e318208f4ab. View

Sanchez-Mejia R, Newman J, Toh S, Yu G, Zhou Y, Halabisky B . Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008; 11(11):1311-8. PMC: 2597064. DOI: 10.1038/nn.2213. View

Bonnot O, Gama C, Mengel E, Pineda M, Vanier M, Watson L . Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry. World J Biol Psychiatry. 2017; 20(4):310-319. DOI: 10.1080/15622975.2017.1379610. View

Owen J, Thomas M, Wykle R . Platelet-activating factor. Methods Enzymol. 2007; 434:105-16. DOI: 10.1016/S0076-6879(07)34006-8. View

Liebisch G, Fahy E, Aoki J, Dennis E, Durand T, Ejsing C . Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J Lipid Res. 2020; 61(12):1539-1555. PMC: 7707175. DOI: 10.1194/jlr.S120001025. View

Berry-Kravis E . Niemann-Pick Disease, Type C: Diagnosis, Management and Disease-Targeted Therapies in Development. Semin Pediatr Neurol. 2021; 37:100879. DOI: 10.1016/j.spen.2021.100879. View

Albert O, Friedmann K, Jaeger R, Berry-Kravis E . Low Risk Profile of Long-Term Repeated Lumbar Puncture for Intrathecal Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin in Patients With Niemann-Pick Type C. Pediatr Neurol. 2023; 144:99-103. DOI: 10.1016/j.pediatrneurol.2023.04.009. View

Vanier M . Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta. 1983; 750(1):178-84. DOI: 10.1016/0005-2760(83)90218-7. View

10.

Sidhu R, Mondjinou Y, Qian M, Song H, Kumar A, Hong X . -acyl--phosphocholineserines: structures of a novel class of lipids that are biomarkers for Niemann-Pick C1 disease. J Lipid Res. 2019; 60(8):1410-1424. PMC: 6672039. DOI: 10.1194/jlr.RA119000157. View

11.

Santos-Lozano A, Villamandos Garcia D, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N . Niemann-Pick disease treatment: a systematic review of clinical trials. Ann Transl Med. 2016; 3(22):360. PMC: 4701532. DOI: 10.3978/j.issn.2305-5839.2015.12.04. View

12.

Rodriguez-Lafrasse C, Rousson R, Pentchev P, Louisot P, Vanier M . Free sphingoid bases in tissues from patients with type C Niemann-Pick disease and other lysosomal storage disorders. Biochim Biophys Acta. 1994; 1226(2):138-44. DOI: 10.1016/0925-4439(94)90021-3. View

13.

Kita Y, Ohto T, Uozumi N, Shimizu T . Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta. 2006; 1761(11):1317-22. DOI: 10.1016/j.bbalip.2006.08.001. View

14.

Bolton S, Soran V, Marfa M, Imrie J, Gissen P, Jahnova H . Clinical disease characteristics of patients with Niemann-Pick Disease Type C: findings from the International Niemann-Pick Disease Registry (INPDR). Orphanet J Rare Dis. 2022; 17(1):51. PMC: 8842861. DOI: 10.1186/s13023-022-02200-4. View

15.

Pallottini V, Pfrieger F . Understanding and Treating Niemann-Pick Type C Disease: Models Matter. Int J Mol Sci. 2020; 21(23). PMC: 7730076. DOI: 10.3390/ijms21238979. View

16.

Braga S . Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases. Biomolecules. 2023; 13(4). PMC: 10136110. DOI: 10.3390/biom13040666. View

17.

Jiang X, Sidhu R, Mydock-McGrane L, Hsu F, Covey D, Scherrer D . Development of a bile acid-based newborn screen for Niemann-Pick disease type C. Sci Transl Med. 2016; 8(337):337ra63. PMC: 5316294. DOI: 10.1126/scitranslmed.aaf2326. View

18.

Vanier M . Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res. 1999; 24(4):481-9. DOI: 10.1023/a:1022575511354. View

19.

Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R . Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci. 2002; 22(5):1679-89. PMC: 6758870. View

20.

Vanier M . Niemann-Pick disease type C. Orphanet J Rare Dis. 2010; 5:16. PMC: 2902432. DOI: 10.1186/1750-1172-5-16. View